99200-09-6

99200-09-6 structure

Name: Nebivolol
Chemical Name: 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]
CAS Number: 99200-09-6
Molecular Formula: C₂₂H₂₅F₂NO₄
Molecular Weight: 405.43500
Catalog: API Circulatory system medication Beta-adrenergic receptor blocker
Create Date: 2018-12-20 12:06:17
Modify Date: 2025-08-25 11:37:17
(Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol. Nebivolol is a selective β1-adrenergic receptor antagonist with an IC50 value of 0.8 nM. Nebivolol can prevent up-regulation of Nox2/NADPH oxidase and lipoperoxidation in the early stages of ethanol-induced cardiac toxicity. Vasodilatory activity[1][2].

Name	2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]
Synonyms	Nebivolol MFCD00865796 (S,R,R,R)-NEBIVOLOL-D2,15N HYDROCHLORIDE Nibivolol rac-nebivolol NEBIVOLOLHCL NEBIVOLOL HYDROCHLORIDE NEBIVOLOL-D4

Description	(Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol. Nebivolol is a selective β1-adrenergic receptor antagonist with an IC50 value of 0.8 nM. Nebivolol can prevent up-regulation of Nox2/NADPH oxidase and lipoperoxidation in the early stages of ethanol-induced cardiac toxicity. Vasodilatory activity[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor
Target	IC50: 0.8 nM (β1-adrenergic receptor)[1]
In Vivo	Nebivolol (10 mg/kg; daily for 7 days) markedly improves endothelial dysfunction and increases P-VASP levels; prevents NOS III uncoupling; significantly inhibit NADPH oxidase in Angiotensin II-treated rats[3].
References	[1]. do Vale GT, et al. Nebivolol Prevents Up-Regulation of Nox2/NADPH Oxidase and Lipoperoxidation in the Early Stages of Ethanol-Induced Cardiac Toxicity. Cardiovasc Toxicol. 2021 Mar;21(3):224-235. [2]. Cockcroft JR, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995 Sep;274(3):1067-71. [3]. Oelze M, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006 Oct;48(4):677-84.

682359-63-3

797054-41-2

~51%

99200-09-6

Literature: EGIS GYOGYSZERGYAR RT. Patent: WO2004/41805 A1, 2004 ; Location in patent: Page 69 ;

99199-90-3

99200-09-6

Literature: WO2011/98474 A1, ;

103-49-1

99200-09-6

Literature: WO2011/98474 A1, ;

100-46-9

99200-09-6

Literature: WO2011/98474 A1, ;